Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies

J Cheminform. 2018 Feb 20;10(1):6. doi: 10.1186/s13321-018-0261-3.


Given that many antifungal medications are susceptible to evolved resistance, there is a need for novel drugs with unique mechanisms of action. Inhibiting the essential proton pump Pma1p, a P-type ATPase, is a potentially effective therapeutic approach that is orthogonal to existing treatments. We identify NSC11668 and hitachimycin as structurally distinct antifungals that inhibit yeast ScPma1p. These compounds provide new opportunities for drug discovery aimed at this important target.

Keywords: Antifungal; Computer modeling; Drug resistance; In vitro evolution; P-type ATPase; PMA1; Saccharomyces cerevisiae.